Vir Biotechnology, Inc. (VIR)
| Market Cap | 4.80B |
| Revenue (ttm) | 72.63M |
| Net Income (ttm) | -390.34M |
| Shares Out | 130.04M |
| EPS (ttm) | -3.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $36.89 |
| Previous Close | $37.35 |
| Change ($) | -0.46 |
| Change (%) | -1.23% |
| Day's Open | 37.35 |
| Day's Range | 36.10 - 37.41 |
| Day's Volume | 458,161 |
| 52-Week Range | 25.31 - 141.01 |
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter end...
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with chronic hepatitis B virus (HBV) infecti...
Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.
The sample size was small, but the results were impressive.
Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. The re...
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents –
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make b...
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients with mi...
– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression ...
Coronavirus players may deliver strong returns well into the future.
– Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET – – Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET –
SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at...
Vir's antibody treatment is addressing one of the biggest COVID challenges.
FDA approves Vir Biotechnology antibody drug for emergencies
George Scangos, President and CEO of Vir Biotechnology, joined Yahoo Finance's Julia LaRoche and Adam Shapiro to discuss the latest on the company's COVID-19 antibody treatment. Watch the 2021 Berkshire...
GlaxoSmithKline and Vir Biotechnology won FDA authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. The post The Surprising Move Vir Stock Made After Winning Covid Drug Autho...
Vir Biotechnology Inc (NASDAQ: VIR) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug Adm...
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline Plc (NYSE: GSK) for treating mild-to-moderate C...
– Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial –
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
The European Medicines Agency's advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) antibody COVID-1...
– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –
– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –
– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter end...
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination wi...
DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that ...
Vir is developing treatments in billion-dollar markets.
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19 GSK and Vir continue discussions with global regulators to make VIR-7831 available to patient...
One of the three clearly has the most upside potential.
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations –
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat a...
Vir Biotechnology Inc (NASDAQ: VIR) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibody main...
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern –
Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-admi...
INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced...
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investi...
GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.
LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Fo...
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advised to co...
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are...
Short-term investors may not see the long-term potential.
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advised to c...
Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136)....
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are...
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor...
About VIR
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Bri... [Read more...]
| Industry Biotechnology | IPO Date Oct 11, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol VIR |
Financial Performance
In 2020, VIR's revenue was $76.37 million, an increase of 843.86% compared to the previous year's $8.09 million. Losses were -$298.67 million, 71.0% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is 81.17, which is an increase of 120.03% from the latest price.